ARQL ArQule Inc.

9.66
+0.15  (+2%)
Previous Close 9.51
Open 9.51
Price To Book 7.61
Market Cap 1,166,891,162
Shares 120,733,695
Volume 3,505,280
Short Ratio
Av. Daily Volume 2,238,159
Stock charts supplied by TradingView

NewsSee all news

  1. ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting

    Conference call and webcast with ArQule management to be held on Monday, December 9, 2019 at 8:15 a.m. EST ArQule management to hold an Investor Event on Monday, December 9, 2019 from 8:00-10:00 p.m. EST in Orlando,

  2. ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK. About ArQule ArQule

  3. ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

    ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced partial responses (PRs) as of July 19th, the cutoff date for data

  4. ArQule Reports Third Quarter 2019 Financial Results

    Conference call scheduled today at 9:00 a.m. ET ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019, the Company reported a net

  5. ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting

    ArQule, Inc. (NASDAQ:ARQL) today announced that it will be presenting research on the company's pan-AKT inhibitor, miransertib (ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting being held from October

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 MOSAIC initiation of dosing announced October 2, 2019.
ARQ 092
Overgrowth Diseases
Phase 1/2 trial ongoing.
Derazantinib (ARQ 087)
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer
Phase 1b data due 2H 2019.
Miransertib - ARQ 092
Solid tumors
Phase 1 presentation at ASH December 9, 2019 at 6pm EST.
ARQ 531
B-cell malignancies
Phase 1b trial ongoing.
ARQ 751
Solid tumors
Phase 1/2 trial to be initiated mid-2019.
Derazantinib (BAL087) and Atezolizumab (Tecentriq)
Urothelial cancer

Latest News

  1. ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting

    Conference call and webcast with ArQule management to be held on Monday, December 9, 2019 at 8:15 a.m. EST ArQule management to hold an Investor Event on Monday, December 9, 2019 from 8:00-10:00 p.m. EST in Orlando,

  2. ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK. About ArQule ArQule

  3. ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies

    ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced partial responses (PRs) as of July 19th, the cutoff date for data

  4. ArQule Reports Third Quarter 2019 Financial Results

    Conference call scheduled today at 9:00 a.m. ET ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019, the Company reported a net

  5. ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting

    ArQule, Inc. (NASDAQ:ARQL) today announced that it will be presenting research on the company's pan-AKT inhibitor, miransertib (ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting being held from October

  6. ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum

    MOSAIC trial represents the first registrational trial for Proteus Syndrome and PIK3CA-related overgrowth spectrum ArQule, Inc. (NASDAQ:ARQL), today announced that the first patient was dosed in the registrational

  7. ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 2019 Cantor Global Healthcare

  8. ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit

  9. ArQule to Participate in Citi's 14th Annual Biotech Conference on September 4, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial Officer, will attend Citi's investor conference on Wednesday, September 4, 2019 at the Four